Diagnosis

PROFILUX Lung Cancer diagnostic project receives funding from the EU Eurostars Programme and CDTI

April 1st, 2020 The project proposal named ‘PROFILUX – Saliva- and blood-based lung cancer detection based on tumour auto-antibody profiling’ has been selected to receive funding from the EU Eurostars Programme. The company received the official communication in January and the project started on April. The international research consortium where PROALT participates is leaded by [...]

2020-11-27T14:03:08+00:001 April 2020|Tags: , , , , |

Successful start of the clinical validation study of COLODETECT® test

23rd, April 2019 Protein Alternatives S.L. (PROALT) has begun the clinical validation study of its blood-based diagnostic test for colorectal cancer in Luminex® and ELISA-based formats. COLODETECT® test is based on detecting in blood the autoantibodies (AAbs) generated by the human body against proteins related to the colorectal cancer tumor, known as tumor-associated antigens [...]

2020-05-06T07:50:27+00:0023 April 2019|Tags: , |

Presentation of ColoDetect project in the European Commission booth at BIO 2016

10th, June 2016 PROALT has been selected by Enterprise Europe Network (EEN) as a successfully funded company and invited to present its ColoDetect project in the European Commission's booth #5977 at BIO International Convention trade fair. The event, hold in San Francisco (United States), took place on Wednesday 8 June 2016. PROALT presented the key [...]

2020-05-05T15:35:38+00:008 June 2016|Tags: , , |

PROALT has launched ColoDetect website to disseminate project results

1st, April 2016 ColoDetect project announces the launch of its website. ColoDetect is a project funded by the European Union through the H2020 SME Instrument Phase 2 and developed by Protein Alternatives (PROALT). The project started in October 2015 and will run for three years. Its objective is the development and commercialization of a blood-based [...]

2020-05-06T07:48:24+00:001 April 2016|Tags: , , |

PROALT receives H2020-SME Instrument funding to develop ColoDetect project

October 1st, 2015 COLODETECT, a proposal submitted by the Spanish biotechnology company PROALT, has been selected to receive EU funding from H2020 SME Instrument. In total, the Commission received 580 project proposals from European SMEs by the first cut-off date of the so-called Horizon 2020’s SME Instrument Phase 2. PROALT is the only Spanish company [...]

2020-05-05T15:36:39+00:001 October 2015|Tags: , , , |

ColoDetect project: featured news in ‘El Mundo’, one of the main national newspapers

May 6th, 2015 The 'Innovators' supplement of the 'El Mundo' newspaper, one of the most widely distributed journals in Spain, has interviewed Dr Juan Ignacio Imbaud, R&D Director of the biotech company Protein Alternatives (Madrid, Spain). The reason was the recent approval of the project named COLODETECT, which was presented by the company to the [...]

2020-05-05T15:37:22+00:005 June 2015|Tags: , , |

ColoDetect project: selected to receive funding from the EU Horizon 2020 Programme

 January 10th, 2015 Protein Alternatives' project proposal named 'ColoDetect - Development of a novel blood-based diagnostic test for colorectal cancer' has been selected to receive funding from the EU Framework Programme Horizon 2020 SME Instrument. The official communication was received by the company in December and the firm is negotiating the grant conditions at the [...]

2020-05-05T15:37:50+00:0010 January 2015|Tags: , , , |
Go to Top